News
The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu ...
Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.
We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the ...
Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...
Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...
Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...
Explore more
Bristol-Myers Squibb Company (NYSE: BMY) is one of the best cheap stocks under $50 to buy now. In a report released on July ...
Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...
Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients. The list price for Eliquis (apixaban) is ...
An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...
Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results